ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 04, 2021 16:15 ET | ARCA biopharma, Inc.
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 ...
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement
July 07, 2021 08:00 ET | ARCA biopharma, Inc.
Provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications WESTMINSTER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma,...
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 16:15 ET | ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA...
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
March 18, 2021 16:30 ET | ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating...
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
December 15, 2020 08:30 ET | ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19
September 21, 2020 08:00 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
May 28, 2020 08:00 ET | ARCA biopharma, Inc.
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...
Logo.png
Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula
February 26, 2020 07:00 ET | Guardion Health Sciences, Inc.
Guardion® has signed a Letter of Appointment with Ho Wah Genting Berhad (HWGB) to create a new formula, designed to enhance the immune system.The formula will be a unique and exclusive brand of HWGB ...